Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Closed loop systems to be considered for all who could benefit in Scotland
In Autumn 2021, JDRF responded to a call for evidence from the Scottish Health Technologies Group (SHTG), who sought views from patient representatives on the benefits and considerations of closed loop systems for people with type 1 diabetes.
JDRF recommended that everyone with type 1 diabetes could benefit from closed loop technology, and diabetes appointments should include informed discussions about the technology’s suitability for them. JDRF is pleased that this has been taken on board by the Scottish Health Technology Group when putting forward its recommendations to NHS Scotland.
The Group’s report acknowledges that rapidly advancing diabetes technologies, such as closed loop systems and the artificial pancreas, have the potential to transform the lives of people living with type 1 diabetes.
As such, they recommend that closed loop systems should be made available to all people with type 1 diabetes who have difficulty meeting their blood glucose targets, are at high risk of severe hypoglycaemia, have reduced awareness of hypoglycaemia, or are experiencing diabetes distress, which is likely to be improved by moving to a closed loop system.
People who are meeting their blood glucose targets using their current technology are recommended to remain using it, but this will be “subject to their circumstances and quality of life.” This person-centred approach that gives greater weight to lived experience and patient preference is a pivotal step towards equal access to diabetes technology in Scotland.
JDRF’s Policy and Public Affairs Manager, Rachael Chrisp, who gave evidence to the consultation, said: “People with type 1 diabetes who already use closed loop systems consistently tell JDRF about its massive impact on improving their wellbeing, so it was crucial that our evidence highlighted the quality of life and mental health benefits of this technology; as well as the improvements in HbA1c that reduce costs to the NHS in the longer term.
“We are pleased to have been able to advocate for the widened access to this technology that the report recommends, and see a real consideration for quality of life in the recommendations.”
These recommendations will now be put to NHS Scotland, making this report a crucial step towards enabling thousands more people with type 1 diabetes to access this ground breaking closed loop technology.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
Abbott has announced that its FreeStyle Libre® 3 sensor is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab’s CamAPS FX mobile app.